Emcure Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Profit Before Tax
1,287.00
971.00
727.00
747.00
972.00
657.00
Adjustment
554.00
551.00
543.00
492.00
398.00
582.00
Changes In working Capital
-530.00
-424.00
50.00
-292.00
-291.00
-334.00
Cash Flow after changes in Working Capital
1,311.00
1,098.00
1,320.00
947.00
1,079.00
904.00
Cash Flow from Operating Activities
943.00
851.00
1,097.00
746.00
768.00
704.00
Cash Flow from Investing Activities
-1,174.00
-96.00
-714.00
-467.00
-574.00
-256.00
Cash Flow from Financing Activities
343.00
-813.00
-164.00
-145.00
-151.00
-188.00
Net Cash Inflow / Outflow
112.00
-58.00
218.00
133.00
41.00
259.00
Opening Cash & Cash Equivalents
-14.00
43.00
-174.00
-308.00
-350.00
-609.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
97.00
-14.00
43.00
-174.00
-308.00
-350.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Emcure Pharma
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
1287.14
1377.65
-90.00
-6.57%
Adjustment
554.62
163.46
391.00
239.30%
Changes In working Capital
-530.13
-652.93
122.00
18.81%
Cash Flow after changes in Working Capital
1311.63
888.18
423.00
47.68%
Cash Flow from Operating Activities
943.55
529.19
414.00
78.30%
Cash Flow from Investing Activities
-1174.9
-428.92
-746.00
-173.92%
Cash Flow from Financing Activities
343.43
-167.92
510.00
304.52%
Net Cash Inflow / Outflow
112.08
-67.65
179.00
265.68%
Opening Cash & Cash Equivalents
-14.31
175.12
-189.00
-108.17%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
97.77
107.47
-10.00
-9.03%
Cash Flow - Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 10.78% vs -22.38% in Mar 2025
Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
943.55
851.71
10.78%






